The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Feb. 11, 2020
Filed:
Jun. 28, 2018
Applicant:
Melt Pharmaceuticals, Inc., San Diego, CA (US);
Inventors:
Mark Baum, San Diego, CA (US);
John Berdahl, Sioux Falls, SD (US);
William Wiley, Chagrin Falls, OH (US);
Dennis Elias Saadeh, Irvine, CA (US);
Assignee:
Melt Pharmaceuticals, Inc., San Diego, CA (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/5517 (2006.01); A61K 47/22 (2006.01); A61K 47/26 (2006.01); A61K 47/34 (2017.01); A61K 47/42 (2017.01); A61K 47/44 (2017.01); A61K 9/00 (2006.01); A61P 23/02 (2006.01); A61K 31/138 (2006.01); A61K 47/10 (2017.01); A61K 45/06 (2006.01); A61K 31/4178 (2006.01); A61K 9/06 (2006.01); A61K 9/20 (2006.01); A61K 9/02 (2006.01); A61K 9/08 (2006.01); A61K 31/135 (2006.01); A61K 31/403 (2006.01);
U.S. Cl.
CPC ...
A61K 31/5517 (2013.01); A61K 9/0014 (2013.01); A61K 9/0019 (2013.01); A61K 9/0031 (2013.01); A61K 9/0043 (2013.01); A61K 9/0053 (2013.01); A61K 9/02 (2013.01); A61K 9/06 (2013.01); A61K 9/08 (2013.01); A61K 9/2031 (2013.01); A61K 31/135 (2013.01); A61K 31/138 (2013.01); A61K 31/4178 (2013.01); A61K 45/06 (2013.01); A61K 47/10 (2013.01); A61K 47/22 (2013.01); A61K 47/26 (2013.01); A61K 47/34 (2013.01); A61K 47/42 (2013.01); A61K 47/44 (2013.01); A61P 23/02 (2018.01); A61K 31/403 (2013.01); A61K 2300/00 (2013.01);
Abstract
Pharmaceutical compositions and methods for inducing conscious sedation using such compositions are described, the compositions comprising a benzodiazepine-based compound, a NMDA antagonist, and optionally a β-blocker, antiemetic, an NSAID, and/or an antihistamine medication. Methods for fabricating the compositions and using them for anesthesiological applications are also described.